MedTrace Logo

The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19

NCT04273581 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-02-21

No results posted yet for this study

Summary

In view of the fact that there is currently no effective antiviral therapy, the prevention or treatment of lung injury caused by COVID-19 can be an alternative target for current treatment. Patients with severe COVID-19 have rapid disease progression and high mortality. There is currently no effective treatment method, which may be related to the excessive immune response caused by cytokine storm. This study will evaluate thalidomide combined with low-dose hormone adjuvant therapy for severe COVID-19 Patient effectiveness and safety.

Conditions

  • COVID-19 Thalidomide

Interventions

DRUG

placebo

100mg/d，qn，for 14 days.

DRUG

Thalidomide

100mg/d，qn，for 14 days.

Sponsors & Collaborators

  • Second Affiliated Hospital of Wenzhou Medical University

    collaborator OTHER

  • Wenzhou Central Hospital

    collaborator OTHER

  • First Affiliated Hospital of Wenzhou Medical University

    lead OTHER

Principal Investigators

  • Jinglin Xia, MD · First Affiliated Hospital of Wenzhou Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-18
Primary Completion
2020-04-30
Completion
2020-05-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04273581 on ClinicalTrials.gov